Navigation Links
MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
Date:4/15/2008

vivo systems and Phase 1 data in mild to moderate asthmatic volunteers demonstrated the safety and tolerability of the monoclonal antibody, thus supporting its continued development.

About Interleukin-13 (IL-13)

Preclinical data has demonstrated that IL-13 plays an important role in asthma. It is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-13 in animal models has been shown to result in many of the features associated with human asthma. IL-13 is believed to be a relevant target for treating asthma, considering its potential role in airway obstruction and in chronic airways remodeling, as seen in animal models.

Clinical Development in Asthma

MedImmune has multiple approaches in development targeting asthma. Currently, in human testing the company has antibodies targeting IL-9 (MEDI 528) and IL-13 (CAT-354), each in Phase 2 development, and an anti-IL-5 receptor (MEDI 563), which is in Phase 1 development. In addition, the company has a number of antibodies that are anticipated to be designated as drug candidates.

About Asthma

Asthma is a chronic disease of the airways that may cause wheezing, breathlessness, chest tightness and coughing. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 30 million Americans reported having a history of asthma in 2003, including nine million children. About 20 million said they currently had asthma. In 2000, the CDC reported that there were more than 10 million asthma-related outpatient visits to private physician offices and hospital clinics. The National Institutes of Health (NIH) have estimated asthma-related healthcare costs in the U.S. at $14 billion annually.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is f
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
4. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
5. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... NEW YORK, December 16 ... the publication of GFT505 (80 mg/day),data ... 50 internationally,recognized expert scientists and clinicians ... the continuing role of generic lipid-modifying,treatments, ... which is commonly observed in patients ...
(Date:12/16/2009)... 16 Verathon®, maker of BladderScan® ... that portable bladder volume ultrasound is now ... for the Prevention of Catheter-Associated Urinary Tract ... introduced in early November 2009, replace the ... The guidelines are located on the ...
(Date:12/16/2009)... Dec. 16 Greenway Medical Technologies, Inc. ... health record (EHR), practice management and interoperability solution, ... KLAS" awards in the annual 2009 Top ... Professional Services report. ,, For practices having ... Chart was named Best in KLAS in ambulatory ...
Breaking Medicine Technology:International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Philips Helps Hospitals Strike Balance Between Innovation and Value 6553 1Philips Helps Hospitals Strike Balance Between Innovation and Value 6553 2Philips Helps Hospitals Strike Balance Between Innovation and Value 6553 3Philips Helps Hospitals Strike Balance Between Innovation and Value 6553 4STALLERGENES is Granted a Marketing Authorization for Oralair 28R 29 in Europe 14985 1STALLERGENES is Granted a Marketing Authorization for Oralair 28R 29 in Europe 14985 2STALLERGENES is Granted a Marketing Authorization for Oralair 28R 29 in Europe 14985 3Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 1Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 2Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 3Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 4Clemente 26apos 3Bs Anatomy Rohen 26apos 3Bs Photographic Anatomy and Moore 26apos 3Bs Clinical Anatomy Customizable Apps Now Available on App Store 62182 5
... April 27 Facet Solutions, Inc. today announced that ... in the United States. The ACADIA(TM) Facet Replacement Pivotal ... the second generation design technology from Facet Solutions, Inc. ... and at the same time restore anatomic motion and ...
... Combination of R7227, protease inhibitor, and R7128, nucleoside polymerase ... patients with hepatitis C -NUTLEY, N.J., BRISBANE, Calif., ... (Nasdaq: ITMN ) and Pharmasset (Nasdaq: ... their innovative, interferon-free regimen of direct acting antiviral (DAA) ...
Other Medicine Technology:Facet Solutions, Inc. Expands U.S. Pivotal Study With Next Generation Implant System 2Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 2Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 3Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 4Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 5Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 6Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 7Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 8Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 9Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 10Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 11
(Date:12/16/2009)... widely used human embryonic stem cell lines lack genetic ... must be addressed to ensure that all sectors of ... University of Michigan research team. ,, In the first ... 47 embryonic stem cell lines, including most of the ... determined the genetic ancestry of each line and found ...
(Date:12/16/2009)... Dec. 16 HealthSciences Institute will ... care professionals, teams and organizations who serve ... chronic diseases in employer, health plan, medical ... collaborative will offer free, noncommercial webinars on ... disease prevention, management and care improvement. Each ...
(Date:12/16/2009)... Scientists pinpoint seven that increase susceptibility to disease ... genes associated with increased susceptibility to leprosy have ... , The researchers, who analyzed more than 10,000 ... in China, said their discovery highlights the important ... the development of leprosy. , "Though leprosy is ...
(Date:12/16/2009)... Research teams led by the Wellcome Trust Sanger Institute ... , All cancers are caused by mutations in the ... person,s lifetime. The studies, of a malignant melanoma and ... all the mutations in the genomes of two cancers. ... each year: almost all are associated with smoking. The ...
(Date:12/16/2009)... Florida researchers at work on a malaria elimination study ... spread of the disease using cell phone records. , ... determine how often residents of Zanzibar travel and where ... off the coast of Tanzania in East Africa, Zanzibar ... commissioned the study as part of deliberations on whether ...
Breaking Medicine News(10 mins):Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Leprosy Genes Identified 2Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3
... Physical therapy is a cost-effective form of ... Oct. 31 Patients with,diabetes who participate ... resistance exercise demonstrate improvements in glucose control,physical ... a study,published in the November 2008 issue ...
... dedicated to providing information and support for patients, families, and ... spinal cord injury, traumatic brain injury, and amputation. , ... ... 2008 -- Catstrophicinjury.com is a new premier one-stop ...
... Aurora Visiting Nurse,Association honored donors, caregivers and friends ... home health and hospice agency,s annual,meeting., (Photo: ... was recognized as corporate friend of,the year for ... "The relationship between Aurora VNA and Children,s Hospital ...
... coumarin, which is related to ingredient in blood thinners ... "vanilla" is often made with a toxic substance called ... Food and Drug Administration warned this week. , ... some blood thinners. Eating foods with coumarin may be ...
... Oct. 31 Blue Cross Blue Shield of Michigan ... bomb threat,received this morning., The closings affect Blue ... and Bricktown Customer Service Center,buildings. The company,s office building ... employees who work in the impacted facilities are,being sent ...
... WASHINGTON, Oct. 31 The National Coalition,for ... the McCain-Palin,campaign for ridiculing the legal rights ... campaign representative Senator Kit Bond,(R-MO), joining Vice ... in Rush,Limbaugh,s hometown of Cape Girardeau, mocking ...
Other Medicine News:Health News:New Research Shows That Combining Aerobic Exercise With High-Force Eccentric Resistance Training Improves Glucose Control in Diabetes Patients 2Health News:New Research Shows That Combining Aerobic Exercise With High-Force Eccentric Resistance Training Improves Glucose Control in Diabetes Patients 3Health News:New Online Support Site Offers Hope, Information, and Help for Patients Who Have Suffered a Catastrophic Injury 2Health News:Aurora Visiting Nurse Association of Wisconsin Honors Supporters, Volunteers 2Health News:Disability Rights Organizations Express Outrage Over Attacks at McCain-Palin Rally 2
Lightweight & portable, compact station. Accurate and speedy measurement, auto-shot function, AI measuring function, focusing indicator....
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Medicine Products: